- Home
- ABTS vs MBRX Comparison
ABTS vs MBRX Comparison
Compare ABTS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.40
HOLD
Current Price
$0.58
Company Overview
Basic Information| Metric | ABTS | MBRX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ABTS | MBRX |
|---|---|---|
| Price | $1.40 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 73.0K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.16 |
| 52 Week High | $10.86 | $7.98 |
Technical Indicators
Market Signals| Indicator | ABTS | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 27.91 |
| Support Level | $0.96 | $0.26 |
| Resistance Level | $1.48 | $2.26 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 60.29 | 75.63 |
Price Performance
Historical Comparison ABTS
MBRX
About ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.